MAIA Biotechnology
Update in progressMAIA (NYSE American)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
MAIA Biotechnology, Inc., and its subsidiaries, is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer. Its lead product, Ateganosine, is a telomere-targeting agent currently in clinical development to assess its activity in non-small cell lung cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
Company score
- Sentiment
- 0.32
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.25
- Governance
- 0.00
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.07
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.20
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNYSE American (ASE)
- LocationUnited States
- CEODr. Vlad Vitoc M.B.A., M.D.
- Founded2018
- Employees13
- Websitemaiabiotech.com
Identifiers
- ISINUS5526411021
- FIGIBBG0113Q7J88
- CUSIP552641102
- CIK0001878313